
1. Lancet. 2021 Nov 6;398(10312):1683-1684. doi: 10.1016/S0140-6736(21)02282-0. Epub
2021 Oct 21.

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.

Hillson K(1), Clemens SC(2), Madhi SA(3), Voysey M(1), Pollard AJ(1), Minassian
AM(4); Oxford COVID Vaccine Trial Group.

Author information: 
(1)Oxford Vaccine Group, University of Oxford, Oxford, OX3 7LE, UK.
(2)Department of Paediatrics, University of Oxford, Oxford, OX3 7LE, UK.
(3)University of the Witwatersrand, Johannesburg, South Africa.
(4)Oxford Vaccine Group, University of Oxford, Oxford, OX3 7LE, UK; Jenner
Institute, University of Oxford, Oxford, OX3 7LE, UK. Electronic address:
angela.minassian@ndm.ox.ac.uk.

DOI: 10.1016/S0140-6736(21)02282-0 
PMCID: PMC8530465
PMID: 34688353  [Indexed for MEDLINE]

Conflict of interest statement: Oxford University has entered into a partnership 
with AstraZeneca for further development of ChAdOx1 nCoV-19 (AZD1222). AJP is
chair of the UK Department of Health and Social Care's Joint Committee on
Vaccination and Immunisation but does not participate in its discussions on
COVID-19 vaccines, is a member of the WHO Strategic Advisory Group of Experts on 
Immunization, and a UK National Institute for Health Research senior
investigator. All other authors declare no competing interests. The members of
the Oxford COVID Vaccine Trial Group are listed in the appendix (pp 5â€“19).

